+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07288359

Study of GVV858 Alone or Combined With Endocrine Therapy for Advanced HRHER2- Breast Cancer and Other Solid Tumors

Led by Novartis Pharmaceuticals · Updated on 2026-10-29

205

Participants Needed

16

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research investigates GVV858 as a single treatment and in combination with endocrine therapies fulvestrant or letrozole for patients with advanced hormone receptor-positive, HER2-negative breast cancer, other solid tumors with CCNE1 amplification, and metastatic castration-resistant prostate cancer. The study is a first-in-human, open-label Phase III trial aiming to understand safety, tolerability, and optimal dosing of GVV858. Participants may receive GVV858 alone or combined with approved endocrine therapies. The Phase I part focuses on dose escalation and safety in three patient groups, with potential expansion by disease type. The Phase II part evaluates GVV858 with fulvestrant in advanced breast cancer patients, including randomized comparison and optional dose optimization. Throughout the study, participants undergo regular monitoring of safety and drug effects up to about two years. This includes tracking adverse events, dose changes, drug levels in the blood, and cancer response measures. The study spans from initial screening, treatment cycles of 28 days, and ongoing assessments to evaluate tolerability and treatment impact.

CONDITIONS

Brief Title

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here